He, Yan-Ling <br/><br/>
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.  [electronic resource] 

 -  Journal of clinical pharmacology  Jan 2008 
 - 85-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0091-2700 
<br/><br/><label>Standard No.: </label>10.1177/0091270007307880  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--administration & dosage<br/>Administration, Oral<br/>Adult<br/>Amlodipine--administration & dosage<br/>Angiotensin II Type 1 Receptor Blockers--administration & dosage<br/>Angiotensin-Converting Enzyme Inhibitors--administration & dosage<br/>Antihypertensive Agents--administration & dosage<br/>Area Under Curve<br/>Cross-Over Studies<br/>Dipeptidyl-Peptidase IV Inhibitors--administration & dosage<br/>Drug Interactions<br/>Female<br/>Half-Life<br/>Headache--chemically induced<br/>Humans<br/>Male<br/>Middle Aged<br/>Nausea--chemically induced<br/>Nitriles--administration & dosage<br/>Pyrrolidines--administration & dosage<br/>Ramipril--administration & dosage<br/>Tablets<br/>Tetrazoles--administration & dosage<br/>Valine--administration & dosage<br/>Valsartan<br/>Vildagliptin